参考文献/References:
[1] Williamson S C, Metcalf R L, Trapani F, et al. Vasculogenic mimicry in small cell lung cancer[J]. Nat Commun,2016,7: 13322.
[2] Hendrix M J, Seftor E A, Seftor R E, et al. Tumor cell vascular mimicry: Novel targeting opportunity in melanoma[J]. Pharmacol Ther,2016,159: 83-92.
[3] Seftor R E, Hess A R, Seftor E A, et al. Tumor cell vasculogenic mimicry: from controversy to therapeutic promise[J]. Am J Pathol, 2012, 181(4): 1115-1125.
[4] Ding J, Jia X, Zuo B, et al. A novel monoclonal antibody targeting a novel epitope of VE cadherin inhibits vasculogenic mimicry of lung cancer cells[J]. Oncol Rep, 2018, 39(6): 2837-2844.
[5] Kim T R, Cho E W, Paik S G, et al. Hypoxia-induced SM22α in A549 cells activates the IGF1R/PI3K/Akt pathway, conferring cellular resistance against chemo- and radiation therapy[J]. FEBS Lett, 2012, 586(4): 303-309.
[6] Park B R, Lee S A, Moon S M, et al. Anthricin-induced cas-pase-dependent apoptosis through IGF1R/PI3K/AKT pathway inhibition in A549 human non-small lung cancer cells[J]. Oncol Rep, 2018, 39(6): 2769-2776.
[7] Srivastava A K, Wang Y, Huang R, et al. Human genome meeting 2016: Houston, TX, USA. 28 February-2 March 2016[J]. Hum Genomics, 2016,10(Suppl 1): 12.
[8] Spiliopoulos K, Peschos D, Batistatou A, et al. Vasculogenic mimicry: lessons from melanocytic tumors[J]. In Vivo, 2015, 29(3): 309-317.
[9] Maniotis A J, Folberg R, Hess A, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry[J]. Am J Pathol, 1999, 155(3): 739-752.
[10] Frisch C M, Zimmermann K, Zilleβen P, et al. Non-small cell lung cancer cell survival crucially depends on functional insulin receptors[J]. Endocr Relat Cancer, 2015, 22(4): 609-621.
[11] Hess A R, Seftor E A, Seftor R E, et al. Phosphoinositide 3-kinase regulates membrane Type 1-matrix metalloproteinase(MMP)and MMP-2 activity during melanoma cell vasculogenic mimicry[J]. Cancer Res, 2003, 63(16): 4757-4762.
[12] Li Y, Sun B, Zhao X, et al. MMP-2 and MMP-13 affect vasculogenic mimicry formation in large cell lung cancer[J]. J Cell Mol Med, 2017, 21(12): 3741-3751.
[13] Zhao S, Qiu Z, He J, et al. Insulin-like growth factor receptor 1(IGF1R)expression and survival in non-small cell lung cancer patients: a meta-analysis[J]. Int J Clin Exp Pathol, 2014, 7(10): 6694-704.
[14] Gest C, Mirshahi P, Li H, et al. Ovarian cancer: Stat3, RhoA and IGF-IR as therapeutic targets[J]. Cancer Lett, 2012, 317(2): 207-217.
相似文献/References:
[1]林清华 吴联平 刘加夫 陈友轩
齐春能 林玉琼 黄小红 郑 静.晚期非小细胞肺癌患者胸水液基细胞学蜡块中新抗体D5F3检测的临床价值[J].福建医药杂志,2019,41(01):3.
LIN Qinghua,WU Lianping,LIU Jiafu,et al.Clinical value of D5F3 in hydrothorax fluid based cytological wax block in patients with advanced non-small cell lung cancer[J].FUJIAN MEDICAL JOURNAL,2019,41(03):3.
[2]陈新富 刘 宁 刘加夫.CK19在非小细胞肺癌淋巴结微转移中的检测价值(附90例分析)[J].福建医药杂志,2020,42(04):6.
CHEN Xinfu,LIU Ning,LIU Jiafu..Detection value of CK19 in lymph node micrometastasis of NSCLC:analysis of 90 cases[J].FUJIAN MEDICAL JOURNAL,2020,42(03):6.
[3]林 潇 陈愉生 李鸿茹.查尔森合并症指数及简化合并症评分对晚期非小细胞肺癌预后的影响[J].福建医药杂志,2020,42(05):23.
LIN Xiao,CHEN Yusheng,LI Hongru.Impact of Charlson comorbidity index and simplified comorbidity score on the prognosis of advanced non-small cell lung cancer[J].FUJIAN MEDICAL JOURNAL,2020,42(03):23.
[4]黄阳,陈静波,林贵山.动态监测循环肿瘤细胞对寡转移非小细胞肺癌联合治疗预后的价值[J].福建医药杂志,2023,45(05):8.
HUANG Yang,CHEN Jingbo,LIN Guishan.Prognostic value of dynamic monitoring of circulating tumor cells in combination therapy for oligometastaticnon-small cell lung cancer[J].FUJIAN MEDICAL JOURNAL,2023,45(03):8.
[5]钟颖,邹立,陈声池.EGFR T790M突变丰度对阿美替尼治疗晚期非小细胞肺癌疗效的影响[J].福建医药杂志,2024,46(01):17.[doi:10.20148/j.fmj.2024.01.005]
ZHONG Ying,ZOU Li,CHEN Shengchi.Relationship between abundance of EGFR T790M mutation and efficacy of Almonertinib in the treatment of advanced non-small cell lung cancer patients[J].FUJIAN MEDICAL JOURNAL,2024,46(03):17.[doi:10.20148/j.fmj.2024.01.005]